Ligand validation:6NNR

CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID

CB3 is a Ligand Of Interest in 6NNR designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6NNR_CB3_B_302	93%	19%	0.076	0.97	1.19	2.25	3	8	0	0	100%	1
6NNR_CB3_A_902	93%	18%	0.085	0.979	1.13	2.4	3	9	0	0	100%	1
4GEV_CB3_B_802	87%	25%	0.081	0.954	1.15	1.91	3	10	0	0	100%	1
2FTO_CB3_X_266	82%	17%	0.087	0.943	1.58	2	6	6	1	0	100%	1
6CDZ_CB3_A_701	53%	20%	0.16	0.922	1.31	2.06	3	11	0	0	100%	1
1KZJ_CB3_A_301	38%	7%	0.194	0.895	1.73	2.99	7	13	2	0	100%	1
2AAZ_CB3_E_2551	92%	5%	0.081	0.973	2.5	2.75	16	15	0	0	100%	0.25
4EIL_CB3_G_702	76%	9%	0.105	0.941	1.96	2.43	8	13	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.